Intra-articular injection of bone marrow-derived mesenchymal stem cells leading to better clinical outcomes without difference in mri outcomes from baseline in patients with knee osteoarthritis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Shin, Y.-S. | - |
dc.contributor.author | Yoon, J.-R. | - |
dc.contributor.author | Kim, H.-S. | - |
dc.contributor.author | Lee, S.-H. | - |
dc.date.accessioned | 2021-10-21T07:40:29Z | - |
dc.date.available | 2021-10-21T07:40:29Z | - |
dc.date.created | 2021-10-21 | - |
dc.date.issued | 2018-09 | - |
dc.identifier.issn | 2234-0726 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/82467 | - |
dc.description.abstract | Purpose: Bone marrow (BM) is frequently used as a source of mesenchymal stem cells (MSCs) because they have a high potential for differentiation. However, it is unclear whether BM-derived MSCs lead to better clinical and magnetic resonance imaging (MRI) outcomes postoperatively. Materials and Methods: This meta-analysis compared the clinical and MRI outcomes in patients with knee osteoarthritis (OA) treated with BM-derived MSCs. Eight studies comparing the clinical and MRI outcomes assessed with various measurement tools in patients with knee OA treated with BM-derived MSCs were included. Results: The range of motion (95% confidence interval [CI], –13.05 to 4.24; p=0.32) and MRI outcomes (95% CI, –0.16 to 1.40; p=0.12) did not differ significantly between the baseline and final follow-up. In contrast, pain (95% CI, 0.89 to 1.87; p<0.001) and functional outcomes (95% CI, 0.70 to 2.07; p<0.001) were significantly improved at the final follow-up when compared to the baseline. Conclusions: This meta-analysis found no significant difference in the tested range of motion and MRI outcomes between the baseline and the final follow-up in patients treated with BM-derived MSCs, whereas significant functional improvement and pain relief were noted when compared with the baseline. Thus, BM-derived MSCs appear to be a viable alternative for patients with knee OA, although long-term and high-quality randomized controlled trials are needed to confirm the clinical benefits. © 2018 KOREAN KNEE SOCIETY. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Knee Society | - |
dc.relation.isPartOf | Knee Surgery and Related Research | - |
dc.title | Intra-articular injection of bone marrow-derived mesenchymal stem cells leading to better clinical outcomes without difference in mri outcomes from baseline in patients with knee osteoarthritis | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 2 | - |
dc.identifier.doi | 10.5792/ksrr.17.201 | - |
dc.identifier.bibliographicCitation | Knee Surgery and Related Research, v.30, no.3, pp.206 - 214 | - |
dc.identifier.kciid | ART002378669 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85059432856 | - |
dc.citation.endPage | 214 | - |
dc.citation.startPage | 206 | - |
dc.citation.title | Knee Surgery and Related Research | - |
dc.citation.volume | 30 | - |
dc.citation.number | 3 | - |
dc.contributor.affiliatedAuthor | Lee, S.-H. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Bone marrow | - |
dc.subject.keywordAuthor | Knee | - |
dc.subject.keywordAuthor | Mesenchymal stem cells | - |
dc.subject.keywordAuthor | Meta-analysis | - |
dc.subject.keywordAuthor | Osteoarthritis | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.